| Filed On | Filing |
|---|---|
| 16 Dec 2025 | 15-12G |
| 21 Nov 2025 | 25-NSE/A |
| 21 Nov 2025 | S-8 POS |
| 21 Nov 2025 | S-8 POS |
| 21 Nov 2025 | SC 14D9/A |
| 21 Nov 2025 |
8-K: Completion of Acquisition or Disposition of Assets; Notice of Delisting or Failure to Satisfy a Listing Rule +2 more
Following the Expiration Time, in accordance with the Purchase Agreement, Buyer commenced a subsequent offering period (the “Subsequent Offering Period”) in accordance with Rule 14d-11 promulgated under the Securities Exchange Act of 193... |
| 21 Nov 2025 | SC TO-T/A |
| 17 Nov 2025 |
Form 4: Powell Fred M, Chief Financial Officer
Returned 65,000 shares to the issuer · Disposed of 124,700 Share Options (Right to Buy) (Disposition to Issuer) |
| 17 Nov 2025 |
Form 4: Wadlinger Mary E., Director
Disposed of 33,390 Share Options (Right to Buy) (Disposition to Issuer) |
| 17 Nov 2025 |
Form 4: Oliger Christy J., Director
Disposed of 33,390 Share Options (Right to Buy) (Disposition to Issuer) |
| 17 Nov 2025 |
Form 4: Noble James, Director
Disposed of 33,390 Share Options (Right to Buy) (Disposition to Issuer) |
| 17 Nov 2025 |
Form 4: Kiener Peter A, Director
Disposed of 33,390 Share Options (Right to Buy) (Disposition to Issuer) |
| 17 Nov 2025 |
Form 4: Backstrom Jay T., Director
Disposed of 33,390 Share Options (Right to Buy) (Disposition to Issuer) |
| 17 Nov 2025 |
Form 4: Wilson Karen J, Director
Returned 10,000 shares to the issuer · Disposed of 33,390 Share Options (Right to Buy) (Disposition to Issuer) |
| 17 Nov 2025 |
Form 4: Dhingra Kapil, Director
Returned 30,000 shares to the issuer · Disposed of 33,390 Share Options (Right to Buy) (Disposition to Issuer) |
| 17 Nov 2025 |
Form 4: Hurly Stephen A, Director
Returned 5,000 shares to the issuer · Disposed of 335,100 Share Options (Right to Buy) (Disposition to Issuer) |
| 13 Nov 2025 | SC 14D9/A |
| 13 Nov 2025 |
8-K: Notice of Delisting or Failure to Satisfy a Listing Rule; Changes in Control of Registrant +1 more
UTRECHT, The Netherlands, and PHILADELPHIA, – November 13, 2025, (GLOBE NEWSWIRE) –LAVA Therapeutics N.V. (“LAVA”) (Nasdaq: LVTX) today announced that 22,877,463 of LAVA’s common shares, representing approximately 87% of LAVA’s outstandi... |
| 13 Nov 2025 | SC TO-T/A |
| 10 Nov 2025 | SC 14D9/A |
Loading...